Inflammatory cytokines TNF-α and IL-17 enhance the efficacy of cystic fibrosis transmembrane conductance regulator modulators

J Clin Invest. 2021 Aug 16;131(16):e150398. doi: 10.1172/JCI150398.

Abstract

Without cystic fibrosis transmembrane conductance regulator-mediated (CFTR-mediated) HCO3- secretion, airway epithelia of newborns with cystic fibrosis (CF) produce an abnormally acidic airway surface liquid (ASL), and the decreased pH impairs respiratory host defenses. However, within a few months of birth, ASL pH increases to match that in non-CF airways. Although the physiological basis for the increase is unknown, this time course matches the development of inflammation in CF airways. To learn whether inflammation alters CF ASL pH, we treated CF epithelia with TNF-α and IL-17 (TNF-α+IL-17), 2 inflammatory cytokines that are elevated in CF airways. TNF-α+IL-17 markedly increased ASL pH by upregulating pendrin, an apical Cl-/HCO3- exchanger. Moreover, when CF epithelia were exposed to TNF-α+IL-17, clinically approved CFTR modulators further alkalinized ASL pH. As predicted by these results, in vivo data revealed a positive correlation between airway inflammation and CFTR modulator-induced improvement in lung function. These findings suggest that inflammation is a key regulator of HCO3- secretion in CF airways. Thus, they explain earlier observations that ASL pH increases after birth and indicate that, for similar levels of inflammation, the pH of CF ASL is abnormally acidic. These results also suggest that a non-cell-autonomous mechanism, airway inflammation, is an important determinant of the response to CFTR modulators.

Keywords: Epithelial transport of ions and water; Genetic diseases; Ion channels; Pulmonology.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aminophenols / administration & dosage
  • Benzodioxoles / administration & dosage
  • Bicarbonates / metabolism
  • Cells, Cultured
  • Cystic Fibrosis / drug therapy
  • Cystic Fibrosis / immunology
  • Cystic Fibrosis / physiopathology
  • Cystic Fibrosis Transmembrane Conductance Regulator / drug effects
  • Cystic Fibrosis Transmembrane Conductance Regulator / genetics
  • Cystic Fibrosis Transmembrane Conductance Regulator / metabolism*
  • Drug Combinations
  • Humans
  • Hydrogen-Ion Concentration
  • Indoles / administration & dosage
  • Infant
  • Infant, Newborn
  • Interleukin-17 / administration & dosage
  • Interleukin-17 / metabolism*
  • Ion Transport
  • Mutation
  • Pyrazoles / administration & dosage
  • Pyridines / administration & dosage
  • Quinolines / administration & dosage
  • Respiratory Mucosa / drug effects
  • Respiratory Mucosa / immunology*
  • Respiratory Mucosa / metabolism*
  • Sulfate Transporters / genetics
  • Sulfate Transporters / metabolism
  • Tumor Necrosis Factor-alpha / administration & dosage
  • Tumor Necrosis Factor-alpha / metabolism*

Substances

  • Aminophenols
  • Benzodioxoles
  • Bicarbonates
  • CFTR protein, human
  • Drug Combinations
  • Indoles
  • Interleukin-17
  • Pyrazoles
  • Pyridines
  • Quinolines
  • SLC26A4 protein, human
  • Sulfate Transporters
  • Tumor Necrosis Factor-alpha
  • elexacaftor, ivacaftor, tezacaftor drug combination
  • Cystic Fibrosis Transmembrane Conductance Regulator